FibroGen (FGEN) Tops Q4 EPS by 21c

FibroGen (NASDAQ: FGEN) reported Q4 EPS of ($0.70), $0.21 better than the analyst estimate of ($0.91). Revenue for the quarter came in at $34.37 million versus the consensus estimate of $24.05 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.

You May Also Be Interested In

• Bristol-Myers Squibb and AstraZeneca said to discuss megamerger - can it happen?
• DA Davidson Reiterates Buy Rating on Tyler Tech (TYL)
• First Business Financial (FBIZ) PT Raised to $80 at DA Davidson